Epicrispr Biotechnologies vs Ray Therapeutics
Epicrispr Biotechnologies vs Ray Therapeutics, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Epicrispr Biotechnologies is on 62/100 and Ray Therapeutics on 53/100.
Where each one leads
Epicrispr Biotechnologies
- our overall score: 62/100 against 53/100
- agent readiness: 39/100 against 21/100
- domain rating: 40/100 against 29/100
Ray Therapeutics
- funding raised: $243M against $90.0M
At a glance
| Measure | Epicrispr Biotechnologies | Ray Therapeutics |
|---|---|---|
| What it is | Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD). | Pioneering vision restoration therapies for severe retinal degenerations. |
| Category | Biotechnology, Therapeutics, Rare Diseases, Epigenetics | Biotechnology, Pharmaceuticals, Healthcare, Medical Devices |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2020 | 2021 |
| Headquarters | South San Francisco, United States | Berkeley, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Epicrispr Biotechnologies | Ray Therapeutics |
|---|---|---|
| Employees | 51 | Not published |
| Total funding | $90.0M | $243M |
| Latest round | Series C | Series B |
| LinkedIn followers | 7,025 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Epicrispr Biotechnologies | Ray Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 53/100 |
| Traction | 57/100 | 40/100 |
| Team | 40/100 | 50/100 |
| Search visibility | 20/100 | 14/100 |
| Quality | 78/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (39/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 29/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Epicrispr Biotechnologies | Ray Therapeutics |
|---|---|---|
| CDN | Cloudflare | Cloudflare |
| CMS | WordPress | WordPress |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Jquery |
| Analytics | Google Analytics 4 | Google Analytics 4 |
Epicrispr Biotechnologies vs Ray Therapeutics: common questions
Which is better, Epicrispr Biotechnologies or Ray Therapeutics?
On our 0-100 score Epicrispr Biotechnologies rates higher (62/100 against 53/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do Epicrispr Biotechnologies and Ray Therapeutics compare on the numbers?
Epicrispr Biotechnologies leads on our overall score (62/100 against 53/100), agent readiness (39/100 against 21/100), domain rating (40/100 against 29/100). Ray Therapeutics leads on funding raised ($243M against $90.0M).
Read the full Epicrispr Biotechnologies review and pricing or the Ray Therapeutics review and pricing. You can also browse other Epicrispr Biotechnologies alternatives we track.